Skip to main content
SpringerLink
Log in

Management of Hypertension

Implications of JNC VI

  • Chapter
Preventive Cardiology

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 137 Accesses

Abstract

Hypertension awareness, treatment, and control rates have increased progressively over the past three decades. Data from the third National Health and Nutrition Examination Survey conducted from 1988–1991 indicate that the percentage of those aware of hypertension had increased to 73% (1). Of those aware, 55% were being treated, and 29% were controlled to a blood pressure of <140/90 mmHg. This information was considered in the preparation of the fifth report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) published in 1993 (2). Unfortunately, these awareness, treatment, and control rates have lessened since publication of the JNC V report (Table 1). Declines in age-adjusted mortality rates for stroke and coronary heart disease appear to be leveling in recent years (3). In fact, the age-adjusted stroke rate actually increased in the United States in 1993 for the first time in more than two decades. The incidence of end-stage renal disease (ESRD), for which high blood pressure is the second most common antecedent, continues to increase, as does the prevalence of congestive heart failure wherein the majority of patients also have antecedent hypertension (4,5).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991 [published erratum appears in Hypertension 1996 May;27(5):1192]. Hypertension 1995; 26: 60–69.

    Article  PubMed  CAS  Google Scholar 

  2. Joint National Committee. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNCV). Arch Intern Med 1993; 153: 154–183.

    Google Scholar 

  3. Data calculated for the National Heart, Lung, and Blood Institute staff, J. Cutler, Principal Investigator, January 1997.

    Google Scholar 

  4. United States Renal Data System 1997 Annual Data Report. Bethesda, MD: US Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Disease.

    Google Scholar 

  5. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–1562.

    Article  PubMed  CAS  Google Scholar 

  6. Joint National Committee. The sixth report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413–2446.

    Google Scholar 

  7. WHO Expert Committee on Hypertension Control. Hypertension Control: Report of a WHO Expert Committee. WHO Technical Report Series, no. 862, 1996, Geneva, Switzerland, World Health Organization.

    Google Scholar 

  8. National High Blood Pressure Education Program (NHBPEP) Working Group. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med 1993; 153: 186–208.

    Google Scholar 

  9. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–313.

    Article  PubMed  CAS  Google Scholar 

  10. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, Phase II (TOHP II). Arch Intern Med 1997; 157: 657–667.

    Google Scholar 

  11. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117–1124.

    Article  PubMed  CAS  Google Scholar 

  12. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739–745.

    Article  PubMed  CAS  Google Scholar 

  13. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214–1218.

    Article  PubMed  CAS  Google Scholar 

  14. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: An overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15: 967–978.

    Article  PubMed  CAS  Google Scholar 

  15. Vasan RS. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996; 156: 1789–1796.

    Article  PubMed  CAS  Google Scholar 

  16. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–1456.

    Google Scholar 

  17. Massie BM, Cleland JG, Armstrong PW, et al. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. J Cardiac Fail 1998; 4: 3–8.

    Article  CAS  Google Scholar 

  18. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349–1355.

    Article  PubMed  CAS  Google Scholar 

  19. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375–380.

    Google Scholar 

  20. Hjalmarson A, Waagstein F. The role of beta-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs 1994; 47 (Suppl 4): 31–39.

    Article  PubMed  Google Scholar 

  21. Eichhorn EJ. The paradox of beta-adrenergic blockade for the management of congestive heart failure. Am J Med 1994; 92: 527–538.

    Article  Google Scholar 

  22. van Zwieten PA. The rationale for the use of beta-blockers in the treatment of congestive heart failure. Am J Geriatr Cardiol 1992;(August):57–61.

    Google Scholar 

  23. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547–1552.

    Article  PubMed  CAS  Google Scholar 

  24. Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (4 Pt 1): 587–594.

    Article  PubMed  Google Scholar 

  25. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–18.

    Article  PubMed  CAS  Google Scholar 

  26. Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997; 277: 1293–1298.

    Article  PubMed  CAS  Google Scholar 

  27. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29: 641–650.

    Article  PubMed  CAS  Google Scholar 

  28. National High Blood Pressure Education Program (NHBPEP) Working Group. 1995 Update of the Working Group Reports on Chronic Renal Failure and Renovascular Hypertension. Arch Intern Med 1996; 156: 1938–1947.

    Google Scholar 

  29. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.

    Google Scholar 

  30. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877–884.

    Article  PubMed  CAS  Google Scholar 

  31. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939–945.

    Article  PubMed  CAS  Google Scholar 

  32. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156: 286–289.

    Article  PubMed  CAS  Google Scholar 

  33. American Diabetes Association. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care 1997; 20 (Suppl 1): S1 - S70.

    Google Scholar 

  34. National High Blood Pressure Education Program (NHBPEP) Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23: 145–158.

    Google Scholar 

  35. Curb JD, Pressel SL, Cutler JA, et al, for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886–1892.

    Article  PubMed  CAS  Google Scholar 

  36. Hennekens CH, Albert CM, Godfried SL, et al. Adjunctive drug therapy of acute myocardial infarction —evidence from clinical trials. N Engl J Med 1996; 335: 1660–1667.

    Article  PubMed  CAS  Google Scholar 

  37. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–497.

    Article  PubMed  CAS  Google Scholar 

  38. National High Blood Pressure Education Program (NHBPEP) Working Group, Roccella EJ, Coordinator. National High Blood Pressure Education Program Working Group Report on hypertension in the elderly. Hypertension 1994; 23: 275–285.

    Google Scholar 

  39. Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993; 329: 1912–1917.

    Article  PubMed  CAS  Google Scholar 

  40. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.

    Google Scholar 

  41. Staessen J, Fagard R, Thijs LG, et al. Morbidity and mortality in the placebo-controlled European trial on isolated systolic hypertension in the elderly. Lancet 1997; 350: 757–764.

    Article  PubMed  CAS  Google Scholar 

  42. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126: 761–767.

    PubMed  CAS  Google Scholar 

  43. Materson BJ, Reda DJ, Cushman WC, et al. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Single-drug therapy for hypertension in men: A comparison of six anti-hypertensive agents with placebo [published correction appears in N Engl J Med 1994;330:1689]. N Engl J Med 1993; 328: 914–921.

    CAS  Google Scholar 

  44. Cruickshank JM, Thorpe JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1: 581–584.

    Article  PubMed  CAS  Google Scholar 

  45. Cooper SP, Hardy RJ, Labarthe DR, et al. The relation between degree of blood pressure reduction and mortality among hypertensives in the Hypertension Detection and Follow-Up Program. Am J Epidemiol 1988; 127: 387–403.

    PubMed  CAS  Google Scholar 

  46. Waller PC, Isles CG, Lever AF, et al. Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? J Hum Hypertens 1988; 2: 7–10.

    PubMed  CAS  Google Scholar 

  47. Fletcher AE, Beevers DG, Bulpitt CJ, et al. The relationship between a low treated blood pressure and IHD mortality: A report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hyper-tens 1988; 2: 11–15.

    CAS  Google Scholar 

  48. Fletcher AE, Bulpitt CJ. How far should blood pressure be lowered? N Engl J Med 1992; 326: 251–254.

    Article  PubMed  CAS  Google Scholar 

  49. Medical Research Council Working Party. The MRC Mild Hypertension Trial: Some subgroup results. In: Strasser T, Gauten D, eds. Mild Hypertension: From Drug Trials to Practice. Raven Press, New York, 1987, pp. 9–20.

    Google Scholar 

  50. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3: 379–392.

    Google Scholar 

  51. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.

    Article  PubMed  CAS  Google Scholar 

  52. Vidt DG, Pohl MA. Aggressive blood pressure lowering is safe, but benefit is still hard to prove. Cleve Clin J Med 1999; 66: 105–111.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Donald G. Vidt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Yale University School of Medicine, New Haven, CT, USA

    JoAnne Micale Foody MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Vidt, D.G. (2001). Management of Hypertension. In: Foody, J.M. (eds) Preventive Cardiology. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-001-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-001-8_6

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6241-9

  • Online ISBN: 978-1-59259-001-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation